The goal is to utilize an understanding of the metabolism and action of antitumor drugs in cancer cells during chemotherapy to optimize the design of treatment regimens for individuals and for specific hematologic diseases. Strong correlations have been established between the response of patients with refractory acute leukemia to high-dose araC therapy and the pharmacokinetics of the active metabolite araCTP in leukemic cells during treatment. These observations were confirmed prospectively and used to design treatment protocols that utilize the cellular pharmacology of araCTP a) to direct the intervals between intermittent doses of araC and b) to indicate the rate of araC administration during a continuous infusion regimen. This application proposes to extend these studies in several directions. First, the cellular pharmacology of araCTP will be evaluated with respect to the response of other hematologic malignancies to high-dose araC to determine the scope of these findings. Second, the cellular metabolism and action of F-araAMP shares many similarities with araC. Therefore, the cellular pharmacology of the active metabolite F-araATP will be evaluated with respect to clinical response during Phase II trials. Third, high-dose araC treatment will be combined with mitoxantrone and with cisplatin to seek higher response rates. This provides the opportunity to determine whether the cellular pharmacology of araCTP continues to provide independent prognostic information during combination chemotherapy, and to investigate if these drugs affect araCTP metabolism. Fourth, DNA damage induced in leukemic cells during therapy with mitoxantrone or with cisplatin will be quantitated by alkaline elution procedures coupled with fluorescence detection. The prognostic value of this evidence of drug action will be evaluated. Finally, knowledge gained in these studies of the metabolism and action of antileukemic drugs in tumor cell during therapy will be used to design new treatment protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA032839-05
Application #
3170684
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1983-08-01
Project End
1991-05-31
Budget Start
1987-06-01
Budget End
1988-05-31
Support Year
5
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ewald, Brett; Sampath, Deepa; Plunkett, William (2008) ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res 68:7947-55
Wang, Yaqing; Liu, Xiaojun; Matsuda, Akira et al. (2008) Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair. Cancer Res 68:3881-9
Liu, Xiaojun; Matsuda, Akira; Plunkett, William (2008) Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Mol Cancer Ther 7:133-42
Ewald, B; Sampath, D; Plunkett, W (2008) Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27:6522-37
Ewald, Brett; Sampath, Deepa; Plunkett, William (2007) H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 6:1239-48
Guo, Lei; Liu, Xiaojun; Nishikawa, Kiyohiro et al. (2007) Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Mol Cancer Ther 6:1501-8
Sampath, Deepa; Cortes, Jorge; Estrov, Zeev et al. (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107:2517-24
Kurtzberg, J; Ernst, T J; Keating, M J et al. (2005) Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23:3396-403
Sampath, Deepa; Rao, V Ashutosh; Plunkett, William (2003) Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22:9063-74
Yang, Li-Ying; Jiang, Hong; Rangel, Kelly M et al. (2003) Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01). Oncol Rep 10:1489-95

Showing the most recent 10 out of 106 publications